美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

ASTRAZENECA PLC ADRhedged

53.28

0.0000

成交量：- -

成交額：- -

市值：159.83萬

市盈率：- -

高：53.28

開：53.28

低：53.28

收：53.28

52周最高：56.90

52周最低：44.36

股本：3.00萬

流通股本：1.00萬

量比：- -

換手率：- -

股息：0.58

股息率：1.08%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

DESTINY-Lung04 III期臨床研究顯示，優赫得®一線治療HER2突變晚期非小細胞肺癌患者的中位無進展生存期達14.3個月

阿斯利康的乳腺癌藥物晚期臨床試驗失敗

阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。

投洽會「金鑰匙」再啓：雙向投資動能強勁，未來產業站上C位

安進（AMGN）聯合療法III期臨床達主要終點

Tozorakimab在OBERON和TITANIA兩項Ⅲ期臨床試驗中，在降低慢阻肺病急性加重方面均顯示出統計學和臨床意義上的顯著改善

商務部新增84個全國重點外資項目

美國食品藥品監督管理局（FDA）加速批准阿斯利康(AZN.O)的Etcamah，用於治療伴有ESR1突變的晚期乳腺癌。

ULTRAGENYX PHARMA股價暴跌45%，創歷史新低，此前該公司罕見病藥物在後期試驗中未能達到主要目標。

安進（AMGN）罕見病藥物Tavneos將於27年3月1日被徹底撤銷英國上市許可

美股異動丨諾華製藥升逾7%，多發性硬化症口服藥後期臨床試驗結果積極

阿斯利康（AZN）抗體偶聯藥物Enhertu聯合療法獲歐盟新適應症批准

拜瑪林製藥（BMRN）與Ascendis就罕見病藥物達成全球專利和解獲最高20%銷售分成

療效碾壓阿斯利康(AZN.US)Imfinzi！Summit(SMMT.US)依沃西單抗III期試驗數據積極，股價應聲大漲

國藥控股與阿斯利康啓動基藥惠民專項合作

阿斯利康長效C5補體抑制劑偉立瑞獲批上市

南方财经网

偉立瑞®在華獲批用於治療成人和1月齡及以上兒童陣發性睡眠性血紅蛋白尿症（PNH）患者

阿斯利康(AZN.US)瑞利珠單抗第3項適應症在中國獲批上市

美股生物醫藥概念持續衝高，Moderna升逾130%，默沙東升逾11%

老虎资讯综合

阿斯利康(AZN.US)單抗新藥兩項適應症在中國上市

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/AZNH/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AZNH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AZNH\",,,,,undefined,":{"symbol":"AZNH","market":"US","secType":"STK","nameCN":"ASTRAZENECA PLC ADRhedged","latestPrice":53.2774,"timestamp":1789492379821,"preClose":53.2774,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":10000,"shares":30000,"eps":0,"marketStatus":"停牌","change":0,"latestTime":"09-15 13:12:59 EDT","open":53.2774,"high":53.2774,"low":53.2774,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":2,"adr":0,"exchange":"NYSE","adjPreClose":53.2774,"dividendRate":0.010836,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AZNH\",,,,,undefined,":{"symbol":"AZNH","floatShares":10000,"roa":"--","roe":"--","lyrEps":0,"shares":30000,"dividePrice":0.57729,"high":53.2774,"amplitude":0,"preClose":53.2774,"low":53.2774,"week52Low":44.36,"pbRate":"--","week52High":56.8955,"institutionHeld":0,"latestPrice":53.2774,"eps":0,"divideRate":0.010836,"volume":0,"delay":0,"ttmEps":0,"open":53.2774,"prevYearClose":54.226,"prevWeekClose":53.2774,"prevMonthClose":53.2774,"prevQuarterClose":53.2774,"fiveDayClose":53.2774,"twentyDayClose":53.2774,"sixtyDayClose":53.2774},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AZNH\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"AZNH","amount":0.57729,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"ASTRAZENECA PLC ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"},{"date":"2024-12-16","symbol":"AZNH","amount":2.71402,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-16","defaultRemindTime":1734359400000,"name":"ASTRAZENECA PLC ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-23","payableDate":"2024-12-16","currency":"USD","dateTimestamp":1734325200000,"payDate":"2024-12-23"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AZNH\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-16","recordDate":"2024-12-16","paymentDate":"2024-12-23","value":2.71402,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.57729,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AZNH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AZNH\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667645276","title":"DESTINY-Lung04 III期臨床研究顯示，優赫得®一線治療HER2突變晚期非小細胞肺癌患者的中位無進展生存期達14.3個月","url":"https://stock-news.laohu8.com/highlight/detail?id=2667645276","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667645276?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:16","pubTimestamp":1789384560,"startTime":"0","endTime":"0","summary":"德曲妥珠单抗组的中位PFS为14.3个月，而帕博利珠单抗联合化疗组为8.3个月。\" 阿斯利康全球执行副总裁、肿瘤研发负责人Susan Galbraith表示：\"DESTINY-Lung04是首项在HER2突变晚期NSCLC患者中，证实PFS优于全球一线标准治疗的III期临床研究。在DESTINY-Lung04临床研究中，德曲妥珠单抗的安全性特征与其已知安全谱总体一致，未发现新的安全性问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5046853_ZH46853_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5046853_ZH46853_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IE00B19Z4B17.USD","LU0128525929.USD","DCO","LU0432979614.USD","LU2237443465.HKD","LU0566484027.USD","BK4231","IE00B66KJ199.SGD","LU2237443978.SGD","LU2237443895.HKD","ADC","NETL","BK4007","BK4187","CR","ORR","LU2456880835.USD","FXN","PFS","LU2089984988.USD","PXI","LU2236285917.USD","LU2462157665.USD","LU1829250122.USD","LU0708994859.HKD","LU1267930573.SGD","LU2237443622.USD","ROKT","BK4585","AZNH","BK4568","LU0289739699.SGD","BK4213","LU0058720904.USD","LU0320765992.SGD","LU1559883803.SGD","LU0109394709.USD","LU2417539215.USD","LU0310800379.SGD","BK4588","IE0031619046.USD","IE00B7SZL793.SGD","PR","BK4161","AZN","LU2237443549.SGD","IE00B3T34201.USD","BK4195","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666574841","title":"阿斯利康的乳腺癌藥物晚期臨床試驗失敗","url":"https://stock-news.laohu8.com/highlight/detail?id=2666574841","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666574841?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:29","pubTimestamp":1789158581,"startTime":"0","endTime":"0","summary":"阿斯利康的乳腺癌药物晚期临床试验失败路透9月11日-阿斯利康（AstraZeneca）AZN.L周五表示，其一款乳腺癌药物在晚期临床试验中未能达到改善无进展生存期的主要目标。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL4T4531G8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZNH","LU0320765992.SGD","LU2456880835.USD","LU0128525929.USD","LU2237443549.SGD","LU0109394709.USD","LU2237443978.SGD","BK4588","LU1829250122.USD","LU2237443382.USD","IE00B3T34201.USD","LU2468319806.SGD","LU2417539215.USD","LU0029864427.USD","LU0058720904.USD","LU2462157665.USD","AZN","BK4585","LU0432979614.USD","LU0889565916.HKD","BK4568","LU0708994859.HKD","LU2236285917.USD","LU2237443895.HKD","LU2237443622.USD","LU2237443465.HKD","LU0289739699.SGD","BK4007","LU1267930573.SGD","LU0310800379.SGD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571008","title":"阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PBPH","LU2322448791.USD","IEHS","HELX","GNOM","LU1992135399.USD","TMED","BIB","FBT","XPH","PPH","BK4588","LU2272731865.HKD","RXL","PBE","LU1992135472.HKD","CANC","SYNB","MEDI","BME","BBP","BBH","XBIX","RSPH","IE00B5TLWC47.USD","IDNA","IBB","BIOY","PJP","IBRN","MRNX","LU2272731600.USD","IEIH","FTXH","AZNH","IYH","LFSC","LU2322448957.HKD","BK4585","PSCH","SBIO","MRNY","WDNA","LU2473716301.USD","LU2272731782.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666533439","title":"投洽會「金鑰匙」再啓：雙向投資動能強勁，未來產業站上C位","url":"https://stock-news.laohu8.com/highlight/detail?id=2666533439","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666533439?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 20:38","pubTimestamp":1788957480,"startTime":"0","endTime":"0","summary":"9月8日至11日，第二十六届中国国际投资贸易洽谈会(以下简称“投洽会”)在厦门国际博览中心举行。本届大会以“扩大双向投资共促全球发展”为永久主题，围绕“投资中国”“中国投资”“国际投 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260909/c679754294.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260909/c679754294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["LU2237443382.USD","LU0289739699.SGD","AZN","LU2236285917.USD","BK4588","LU2456880835.USD","LU2417539215.USD","AZNH","LU0029864427.USD","LU0058720904.USD","LU2237443622.USD","LU0310800379.SGD","LU1829250122.USD","LU2237443978.SGD","LU2468319806.SGD","LU0708994859.HKD","BK4007","LU0128525929.USD","LU0432979614.USD","LU0320765992.SGD","LU2237443895.HKD","BK4585","IE00B3T34201.USD","LU0889565916.HKD","LU2462157665.USD","LU2237443549.SGD","LU2089984988.USD","BK4568","LU2237443465.HKD","LU1267930573.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666712586","title":"安進（AMGN）聯合療法III期臨床達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2666712586","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666712586?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 16:59","pubTimestamp":1788944360,"startTime":"0","endTime":"0","summary":"金吾财经 | 安进公布，双特异性T细胞衔接器Imdelltra联合阿斯利康PD-L1抑制剂英飞凡，在广泛期小细胞肺癌的后期临床试验中实现总生存期延长。这家加州生物制药企业披露III期DeLLphi-305研究中期数据，该试验达成广泛期小细胞肺癌患者总生存期主要终点。该项全球试验评估该组合作为一线维持治疗，受试者既往接受过包含英飞凡的治疗且病情未发生进展。研究同时达成无进展生存期、客观缓解率两项次要终点。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305840","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","AMGN","BK4566","LU0109394709.USD","LU2468319806.SGD","LU2237443978.SGD","LU2112291526.USD","LU2237443895.HKD","BK4581","BIB","AZNH","PJP","LU0889565916.HKD","IE0002141913.USD","LU0128525929.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","LU2242652126.USD","BBH","IE00B4R5TH58.HKD","LU1571399168.USD","BK4533","LU1023059063.AUD","LU0058720904.USD","LU0868494617.USD","LU2456880835.USD","LU0708994859.HKD","IBBQ","LU2242646821.SGD","LU0289739699.SGD","LU0432979614.USD","LU1829250122.USD","IBB","LU2236285917.USD","IE00B2B36J28.USD","PBE","LU2237443622.USD","LU0029864427.USD","BK4139","BK4568","BK4534","BK4585","LU2237443382.USD","LU1267930573.SGD","LU2462157665.USD","LU2089984988.USD","TBXU","SG9999001440.SGD","AZN","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665968376","title":"Tozorakimab在OBERON和TITANIA兩項Ⅲ期臨床試驗中，在降低慢阻肺病急性加重方面均顯示出統計學和臨床意義上的顯著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2665968376","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665968376?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:18","pubTimestamp":1788873480,"startTime":"0","endTime":"0","summary":"OBERON和TITANIA两项Ⅲ期试验的结果令人鼓舞，证实tozorakimab在广泛患者人群中均能降低急性加重风险，有望帮助患者摆脱反复急性加重的困扰，获得全新的治疗选择。Tozorakimab 是首个在广泛慢阻肺病患者人群中显示出减少气道黏液栓堵塞作用的生物制剂3。Tozorakimab总体耐受性和安全性良好，唯一报告的药物不良反应为注射部位反应1,2。目前，tozorakimab已在欧盟、中国等主要市场进入上市许可审评阶段，用于治疗慢性阻塞性肺疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5042444_ZH42444_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5042444_ZH42444_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2237443382.USD","IBBQ","LU2237443895.HKD","LU2456880835.USD","BK4588","BK4568","LU2089984988.USD","LU2462157665.USD","LU0058720904.USD","AZN","BMED","LU2237443465.HKD","LU0708994859.HKD","IBBJ","BK4007","LU2468319806.SGD","LU0289739699.SGD","MDTX","LU0128525929.USD","LU0889565916.HKD","LU2236285917.USD","IE00B3T34201.USD","LU2237443549.SGD","LU0432979614.USD","LU1829250122.USD","AZNH","BK4585","LU2237443622.USD","LU0109394709.USD","LU0320765992.SGD","PSYK","LU1267930573.SGD","LU0310800379.SGD","LU2417539215.USD","LU0029864427.USD","LU2237443978.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665341019","title":"商務部新增84個全國重點外資項目","url":"https://stock-news.laohu8.com/highlight/detail?id=2665341019","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665341019?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 12:05","pubTimestamp":1788840300,"startTime":"0","endTime":"0","summary":"【大河财立方记者程帅星厦门报道】9月8日，大河财立方记者在第二十六届中国国际投资贸易洽谈会(以下简称“投洽会”)上获悉，商务部近日新增84个全国重点外资项目，其中包括6个外资标志性项 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260908/c679692496.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260908/c679692496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["LU2756315318.SGD","LU2168563687.JPY","SKHZ","LU1989771016.USD","LU0158827781.USD","LU2328871848.SGD","LU2168564065.EUR","LU1093756325.SGD","LU2462591350.SGD","LU2471134523.USD","IE00BFTCPJ56.SGD","SG9999001176.USD","LU1023059063.AUD","IE00BWXC8680.SGD","LU2471134796.USD","LU0097036916.USD","CURE","LU0964807845.USD","SKHY","SKHN","BK0188","LU2089283258.USD","LU2360106947.USD","IE00B4JS1V06.HKD","LU2264538146.SGD","LU0823426480.USD","SGXZ31699556.SGD","LU0823397103.USD","LU1974910355.USD","LU1323610961.USD","LU0979878070.USD","LU2265009873.SGD","LU0058720904.USD","SG9999015986.USD","LU0516422366.SGD","BK1589","LU2361044949.HKD","LU1794554557.SGD","LU2236285917.USD","VHT","LU2461242641.AUD","LU0823413587.USD","LU2552382215.SGD","IE00B775H168.HKD","LU2750360997.AUD","IE00BJT1NW94.SGD","LU0061475181.USD","LU2111349929.HKD","BK0028","LU0823416689.USD","SGXZ99366536.SGD","IE00B1XK9C88.USD","LU0353189763.USD","LU0122379950.USD","LU1868837136.USD","LU2237443465.HKD","LU1280957306.USD","LU0689472784.USD","LU0096364046.USD","LU2491049909.HKD","LU0456855351.SGD","SKUU","LU0354030438.USD","IE0004445015.USD","LU2746668461.USD","LU0787776722.HKD","LU0466842654.USD","LU1629891620.HKD","LU2213496289.HKD","IE0001KFT4U8.USD","SG9999018857.SGD","SG9999014898.SGD","LU0327786744.USD","LU0823413660.USD","RXL","SG9999001176.SGD","LU0052750758.USD","SGXZ81514606.USD","AGNG","LU0516422440.USD","GDOC","LU2168564222.USD","LU0856984785.SGD","LU0114720955.EUR","LU2750360641.GBP","LU0708995401.HKD","LU0234572021.USD","LU0348825331.USD","LU1814569148.SGD","SG9999002463.SGD","LU1983299246.USD","SKHYV","IHE","LU0823434583.USD","LU2237438978.USD","LU2237443978.SGD","LU2271345857.HKD","LU1988902786.USD","LU0051755006.USD","LU0109394709.USD","LU2746668974.SGD","IE00BK4W5L77.USD","LU0326950275.SGD","MEDI","LU2357305700.SGD","LU0471298777.SGD","SG9999015978.USD","BK0208","LU0079474960.USD","LU3063872942.SGD","LU1691799644.USD","WDNA","LU2471134879.HKD","LU0029864427.USD","LU0203201768.USD","BK4568","HRTS","LU0128526141.USD","LU1969619763.USD","SKHA","LU2324357040.USD","IE00BJLML261.HKD","MHIP","LU0006306889.USD","LU1069344957.HKD","LU1880383366.USD","IE00B2B36J28.USD","LU1242518931.SGD","LU1720050803.USD","LU0819121731.USD","LU0348735423.USD","LU1868836757.USD","LU0882574139.USD","IYH","BK4533","BK4599","LU2063271972.USD","PPH","LU0029874061.USD","LU2089284900.SGD","LU1868837300.USD","SG9999017495.SGD","LU2211815571.USD","LU0174119429.USD","LU2361044865.SGD","LU1548497426.USD","ILDR","LU0359202008.SGD","LU0225283273.USD","LU2756315664.SGD","LU2468319806.SGD","LU2168564149.EUR","LU1551013425.SGD","LU2417539215.USD","IE00B4R5TH58.HKD","LU2462157665.USD","LU1688375341.USD","SG9999015952.SGD","LU0572944931.SGD","LU0640476718.USD","SGXZ57979304.SGD","SG9999018865.SGD","LU0203202063.USD","LU0256863811.USD","LU0516422952.EUR","LU0823426308.USD","LU1868836591.USD","LU0417516738.SGD","LU2552382058.USD","LU1035775433.USD","IE00B7KXQ091.USD","LU2106854487.HKD","BK0197","LU0198837287.USD","SG9999002562.SGD","LU0238689110.USD","LU2023250330.USD","LU2237443382.USD","LU1242518857.USD","LU1145028129.USD","TMED","IE00B1BXHZ80.USD","BK4581","LU0181495838.USD","MEDX","LLII","TRUH","LLYX","BK1521","LU0516423174.USD","LU1551013342.USD","IE00B3T34201.USD","LU2602419157.SGD","LU2108987350.USD","LU1291159041.SGD","LU2491050154.USD","LU0345770308.USD","LU0359201612.USD","LU1868836914.USD","LU1720051017.SGD","LU2028103732.USD","LU2552382132.HKD","LU0266013472.USD","LU2491050071.SGD","SG9999014880.SGD","LU2023251221.USD","LU2237443549.SGD","LU1979441026.SGD","LU2087625088.SGD","KURE","LU0289739699.SGD","LU0133085943.USD","LU2039709279.SGD","LU0943347566.SGD","LU1366192091.USD","LU0316494557.USD","LU1956131251.USD","LU0820561909.HKD","LU0210536198.USD","BK4585","IE0009355771.USD","LU1917777945.USD","IE0004445239.USD","BK4141","02269","IE0005OL40V9.USD","IE00BJJMRY28.SGD","BK1576","LU0823434740.USD","LU0385154629.USD","LU2168564495.EUR","LU0106261372.USD","LU1829250122.USD","IE00BKPKM429.USD","LU0417517546.SGD","PJP","IE00BJJMRX11.SGD","LU0889565916.HKD","LU2471134952.CNY","SG9999013999.USD","LU1232071149.USD","LU0310800379.SGD","SKHQ","BK1141","LU0471298694.HKD","LU0323591593.USD","IE00BJJMRZ35.SGD","THNR","LU0786609619.USD","SKHU","07709","SKHL","LLY","LU2896262040.SGD","LU0320765992.SGD","LU0158827948.USD","LU1127390331.HKD","IE0002141913.USD","LU0109391861.USD","BK4007","LU1057294990.SGD","LU0820561818.USD","AZNH","IE00BN29S564.USD","ELIL","LU2456880835.USD","OZEM","LU0039217434.USD","SKDD","FTXH","LU0672654240.SGD","WXXWY","LU0516423091.SGD","GB00BDT5M118.USD","BK4534","LU0456846285.SGD","LU0432979614.USD","LU1064131342.USD","LU0353189680.USD","LU2237443895.HKD","LU0708994859.HKD","LU0320765059.SGD","LU0820562030.AUD","LU2023250504.SGD","AZN","LU1267930573.SGD","JDOC","LU0354030511.USD","IE00BKDWB100.SGD","ABB","LU2237443622.USD","LU0588546209.SGD","LU0140636845.USD","HYNX","IE00BFSS7M15.SGD","LU0456827905.SGD","XLV","SG9999014914.USD","LU1093756168.USD","LU0094547139.USD","BK4096","SKHX","LU0683600562.USD","IXJ","LU1061106388.HKD","LU2089984988.USD","LU2361045086.USD","IE00BFSS8Q28.SGD","LU0708995583.HKD","BK0196","SGXZ51526630.SGD","LU1804176565.USD","LU1623119135.USD","LU0128525929.USD","LU0320764599.SGD","LU0307460666.USD","CANC","SK","SG9999014906.USD","BK4588","ELIS","BK4516","LU1712237335.SGD","SG9999015945.SGD","LU0823397285.USD","LU2112291526.USD","LU0417516902.SGD","LLYZ","BK1610","FHLC","LU1720051108.HKD","IE00BK4W5M84.HKD","BK0187","LU0256863902.USD","LU0345770993.USD","LU0882574055.USD","LU0043850808.USD","IE00B0JY6N72.USD","002493","LU1267930730.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665935968","title":"美國食品藥品監督管理局（FDA）加速批准阿斯利康(AZN.O)的Etcamah，用於治療伴有ESR1突變的晚期乳腺癌。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665935968","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665935968?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 03:47","pubTimestamp":1788551256,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4007","LU0320765992.SGD","LU0128525929.USD","LU0289739699.SGD","LU2237443465.HKD","LU2468319806.SGD","LU0889565916.HKD","LABU","LU2237443382.USD","LU2236285917.USD","LU2237443895.HKD","LU1267930573.SGD","LU2237443549.SGD","LU0310800379.SGD","LU0058720904.USD","LU2462157665.USD","LU2089984988.USD","LU0432979614.USD","159151","LU2237443978.SGD","AZN","BK4568","IE00B3T34201.USD","BK4588","LU2456880835.USD","AZNH","BK4585","LU2417539215.USD","LU0109394709.USD","LU0708994859.HKD","LU2237443622.USD","LU1829250122.USD","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664877064","title":"ULTRAGENYX PHARMA股價暴跌45%，創歷史新低，此前該公司罕見病藥物在後期試驗中未能達到主要目標。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664877064","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664877064?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 21:50","pubTimestamp":1788443439,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["AZNH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664194548","title":"安進（AMGN）罕見病藥物Tavneos將於27年3月1日被徹底撤銷英國上市許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2664194548","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664194548?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 19:59","pubTimestamp":1788350357,"startTime":"0","endTime":"0","summary":"金吾财讯 | 英国药品监管机构MHRA宣布，暂停安进（AMGN）罕见病药物Avacopan Vifor（原商品名Tavneos）用于新患者，监管认定支撑该药物获批的关键临床试验数据已不可靠。该药2022年在英国获批，用于治疗两种罕见血管炎症自身免疫病。安进持有美国地区权益，由CSL集团（CSLLY）旗下CSLVifor负责英国等海外市场销售。新规9月1日落地，不再允许新患者启用该药物；为保障现有患者安全，设置6个月过渡用药期，2027年3月1日将彻底撤销其英国上市许可，现有患者可在此期间逐步更换替代治疗方案。安进方面公开表示不认可监管机构的决定，担忧该举措会对罕见病患者造成负面影响。","market":"other","thumbnail":"https://static.szfiu.com/news/20210625/OTU2NGE4NGJmZTIzZDc2N2YxYmJkM2MyMjUzODQzOTQ1NzY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/OTU2NGE4NGJmZTIzZDc2N2YxYmJkM2MyMjUzODQzOTQ1NzY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305627","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4599","LU1983299246.USD","IBBQ","LU0889565916.HKD","BK4533","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","IPOS","BK4139","LU1023059063.AUD","BK4588","LU2468319806.SGD","IBB","LU0868494617.USD","LU0289739699.SGD","AMGN","BK4566","LU1571399168.USD","AZNH","LU0122379950.USD","BK4585","IE0009355771.USD","LU1057294990.SGD","LU2242646821.SGD","IE00B4R5TH58.HKD","SG9999001440.SGD","TBXU","LU0058720904.USD","LU2089984988.USD","LU0320765992.SGD","IE00BFTCPJ56.SGD","LU2242652126.USD","PJP","LU1061106388.HKD","BIB","BK4534","IE0002141913.USD","PBE","IE00BJT1NW94.SGD","LU2112291526.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664521258","title":"美股異動丨諾華製藥升逾7%，多發性硬化症口服藥後期臨床試驗結果積極","url":"https://stock-news.laohu8.com/highlight/detail?id=2664521258","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664521258?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 22:18","pubTimestamp":1788272338,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BBP","MEDI","IBRN","BBH","AZNH","BIB","NVS","LU0070302665.USD","IDNA","LU2473716301.USD","LU0211331839.USD","BK4588","MEDX","GNOM","WDNA","BK4585","IE0002141913.USD","SBIO","PBE","IEIH","PJP","HELX","IE0009355771.USD","IE00BJJMRZ35.SGD","MRNY","PSCH","RXL","FTXH","PBPH","IYH","IE00BFTCPJ56.SGD","PPH","IE00BJT1NW94.SGD","IBB","SYNB","BK4007","MRNX","LFSC","XBIX","XPH","TMED","LU2322448957.HKD","RSPH","IE00B4R5TH58.HKD","LU2272731600.USD","FBT","IEHS","BME","CANC","BIOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664368853","title":"阿斯利康（AZN）抗體偶聯藥物Enhertu聯合療法獲歐盟新適應症批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664368853","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664368853?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 18:36","pubTimestamp":1788258974,"startTime":"0","endTime":"0","summary":"金吾财讯 | 阿斯利康 与第一三共联合宣布，其抗体偶联药物Enhertu联合帕妥珠单抗的组合疗法已正式获得欧盟委员会批准，用于一线治疗不可切除或转移性HER2阳性乳腺癌成年患者。这也是Enhertu在短短两个月内于欧盟获得的第二个新适应症批准。随着这一欧盟监管决定的落地，阿斯利康将向第一三共支付1亿美元的里程碑付款。目前，该疗法已在包括美国、中国在内的全球40多个国家和地区获批上市。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/MWM3M2E1ZjMzOTEwODk1MDE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MWM3M2E1ZjMzOTEwODk1MDE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305553","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2236285917.USD","AZNH","LU2468319806.SGD","LU0058720904.USD","BK4568","BK4588","FSXEmain","IE00B3T34201.USD","LU0320765992.SGD","LU1829250122.USD","AZN","LU2237443978.SGD","LU2456880835.USD","LU1267930573.SGD","BK4585","LU2237443465.HKD","LU2237443895.HKD","LU0310800379.SGD","LU2237443549.SGD","LU2417539215.USD","LU0432979614.USD","LU0109394709.USD","LU0289739699.SGD","LU2089984988.USD","LU2237443382.USD","LU0128525929.USD","LU2462157665.USD","LU0029864427.USD","LU2237443622.USD","LU0708994859.HKD","FESXmain","BK4007","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077819","title":"拜瑪林製藥（BMRN）與Ascendis就罕見病藥物達成全球專利和解 獲最高20%銷售分成","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077819","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077819?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 18:47","pubTimestamp":1788173270,"startTime":"0","endTime":"0","summary":"作为回报，拜玛林制药将向Ascendis授予针对Yuviwel所有现行及潜在适应症以及联合用药方案的专利许可，并撤回在美国国际贸易委员会发起的337调查以及在德国、丹麦、巴西、韩国和美国加州北区法院挂牌的诉讼。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/NDEzNTY0MzU1NjUy.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDEzNTY0MzU1NjUy.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305490","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","BK4139","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","BK4566","BMRN","AZNH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662671167","title":"療效碾壓阿斯利康(AZN.US)Imfinzi！Summit(SMMT.US)依沃西單抗III期試驗數據積極，股價應聲大漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2662671167","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662671167?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 20:32","pubTimestamp":1787747523,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","LU0708994859.HKD","LU2237443978.SGD","BK4585","LU2237443382.USD","LU2468319806.SGD","LU1829250122.USD","III","LU2236285917.USD","LU0432979614.USD","LU2089984988.USD","LU2488822045.USD","LU0109394709.USD","LU1267930573.SGD","LU0128525929.USD","LU0029864427.USD","LU0289739699.SGD","BK4139","BK4134","LU2417539215.USD","LU0310800379.SGD","BK4568","BK4588","AZNH","LU0889565916.HKD","LU2237443465.HKD","SMMT","LU2456880835.USD","IE00B3T34201.USD","LU2237443895.HKD","LU2462157665.USD","LU2237443549.SGD","LU2237443622.USD","LU0320765992.SGD","AZN","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662976179","title":"國藥控股與阿斯利康啓動基藥惠民專項合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2662976179","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662976179?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 11:20","pubTimestamp":1787714411,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1267930573.SGD","BK4588","AZN","AZNH","LU2456880835.USD","LU2468319806.SGD","LU2237443549.SGD","LU2236285917.USD","BK4007","LU0289739699.SGD","LU2462157665.USD","LU0320765992.SGD","LU0128525929.USD","BK4568","LU2089984988.USD","LU2417539215.USD","LU0432979614.USD","LU0029864427.USD","LU2237443465.HKD","LU2237443622.USD","LU2237443895.HKD","IE00B3T34201.USD","LU0058720904.USD","LU0310800379.SGD","LU0889565916.HKD","LU2237443978.SGD","LU0708994859.HKD","LU2237443382.USD","BK4585","LU1829250122.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660286748","title":"阿斯利康長效C5補體抑制劑偉立瑞獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2660286748","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660286748?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 18:58","pubTimestamp":1787223480,"startTime":"0","endTime":"0","summary":"南方财经8月20日电，记者获悉，阿斯利康罕见病业务旗下的长效C5补体抑制剂伟立瑞?（英文商品名：Ultomiris?，通用名：瑞利珠单抗注射液），已获得中国国家药品监督管理局（NMPA）批准，用于成人和1月龄及以上儿童阵发性睡眠性血红蛋白尿症（PNH）患者的治疗。PNH是一种慢性、进行性且危及生命的血液系统罕见疾病。该疾病好发于青壮年，77%的PNH患者在20-40岁发病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608203847950261.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608203847950261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0289739699.SGD","LU0310800379.SGD","LU0058720904.USD","LU0128525929.USD","BK4568","LU2237443978.SGD","LU0889565916.HKD","LU2468319806.SGD","LU0029864427.USD","LU1829250122.USD","BK4585","LU0432979614.USD","LU2237443382.USD","LU2237443465.HKD","LU2237443549.SGD","LU2237443622.USD","LU1267930573.SGD","LU2236285917.USD","IPOS","LU0708994859.HKD","LU2462157665.USD","LU2237443895.HKD","AZN","BK4007","LU2089984988.USD","BK4588","IE00B3T34201.USD","LU0320765992.SGD","AZNH","LU2456880835.USD","LU0109394709.USD","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660284301","title":"偉立瑞®在華獲批用於治療成人和1月齡及以上兒童陣發性睡眠性血紅蛋白尿症（PNH）患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2660284301","media":"美通社","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660284301?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 18:58","pubTimestamp":1787223480,"startTime":"0","endTime":"0","summary":"此次瑞利珠单抗获批，为成人及儿童PNH患者带来了兼具长效性、稳定性和便利性的治疗选择，可实现快速、完全且持续的终末补体抑制。目前，瑞利珠单抗在中国、美国、欧盟、日本等国家和地区获批用于治疗特定的阵发性睡眠性血红蛋白尿症的成人及儿童患者，并在全球多个国家和地区获批多项适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5030457_ZH30457_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5030457_ZH30457_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0289739699.SGD","LU0310800379.SGD","LU0029864427.USD","LU2237443978.SGD","LU0889565916.HKD","LU2089984988.USD","LU0708994859.HKD","LU2456880835.USD","LU0432979614.USD","LU2468319806.SGD","LU2462157665.USD","LU2237443465.HKD","LU2237443622.USD","BK4007","LU1267930573.SGD","BK4568","BK4588","LU2237443895.HKD","IE00B3T34201.USD","AZN","BK4585","LU0058720904.USD","LU0109394709.USD","AZNH","LU0128525929.USD","LU0320765992.SGD","LU2237443549.SGD","LU2236285917.USD","LU2237443382.USD","LU2417539215.USD","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660407362","title":"阿斯利康(AZN.US)瑞利珠單抗第3項適應症在中國獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2660407362","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660407362?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 16:50","pubTimestamp":1787215836,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月20日，国家药品监督管理局官网显示，阿斯利康“瑞利珠单抗”国内再获批一项新适应症，用于治疗阵发性睡眠性血红蛋白尿症。瑞利珠单抗于2025年4月首次获批进入中国，用于治疗抗AChR抗体阳性的成人全身型重症肌无力，后又拓展适应症至NMOSD。瑞利珠单抗此次新适应症获批，成为国内第7款、进口第4款PNH治疗药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482601.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2237443465.HKD","LU1267930573.SGD","LU0128525929.USD","IE00B3T34201.USD","AZNH","LU2462157665.USD","LU2089984988.USD","LU0889565916.HKD","LU2417539215.USD","LU0289739699.SGD","LU2237443622.USD","LU2237443382.USD","LU2237443978.SGD","BK4585","AZN","LU1829250122.USD","LU0310800379.SGD","BK4007","IPOS","LU0320765992.SGD","LU0029864427.USD","BK4568","LU2237443895.HKD","LU0708994859.HKD","LU2237443549.SGD","LU2456880835.USD","LU0432979614.USD","LU2468319806.SGD","LU0058720904.USD","BK4588","LU0109394709.USD","LU2236285917.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156346136","title":"美股生物醫藥概念持續衝高，Moderna升逾130%，默沙東升逾11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156346136","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156346136?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 22:06","pubTimestamp":1787148392,"startTime":"0","endTime":"0","summary":"8月19日，美股生物医药概念持续冲高，$Moderna(MRNA)$涨幅扩大至130%，$默沙东(MRK)$涨超11%，$礼来(LLY)$涨超5%，$辉瑞(PFE)$、$诺和诺德(NVO)$、$阿斯利康(AZN)$等涨约3%。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1829250122.USD","IE0009355771.USD","SG9999014542.SGD","LU2237443622.USD","LU2028103732.USD","LU2491049909.HKD","LU1066053197.SGD","IE00B2B36J28.USD","MRNY","OZEM","LU0289739699.SGD","SG9999017495.SGD","LU2357627491.SGD","LU0094547139.USD","LU1023059063.AUD","LU2324357040.USD","VHT","LU1983299246.USD","LU2456880835.USD","LU0964807845.USD","LU1035775433.USD","LU0689626769.HKD","LU0823434740.USD","LU2237443549.SGD","ILDR","LU2271345857.HKD","LU1232071149.USD","LU2468319806.SGD","LU0689472784.USD","LU2471134879.HKD","LU1923622614.USD","MRNA","LU1064131342.USD","BGIA","LU0868494617.USD","LU2491050071.SGD","SG9999014880.SGD","LU0079474960.USD","LU1934455863.HKD","LU2168564065.EUR","LU0640476718.USD","BK4533","LU2023250504.SGD","LU0323591593.USD","LU0320765646.SGD","LU1623119135.USD","BK4585","LU0265550946.USD","BK4551","IE00BLSP4239.USD","GB00BDT5M118.USD","LU0965509010.AUD","LU0943347566.SGD","GNOM","SG9999018857.SGD","LU1267930730.SGD","LU0353189763.USD","LU0321505868.SGD","AGNG","LU0708994859.HKD","LU0980610538.SGD","LU1894683264.USD","LU2360106947.USD","IE00B775H168.HKD","IE00BN8TJ469.HKD","IE00B3T34201.USD","SG9999002232.USD","LU2756315664.SGD","IE00BSNM7G36.USD","LU2125154778.USD","LU0320765992.SGD","CURE","LU0006306889.USD","LU0882574055.USD","LU0130102774.USD","LU1323610961.USD","LU2237443382.USD","LU2602419157.SGD","LU0417517546.SGD","LU1145028129.USD","LU0385154629.USD","LU1629891620.HKD","SG9999014898.SGD","LU0128525929.USD","RXL","LU1720051017.SGD","LU2237443978.SGD","LU1551013342.USD","IE00BK4W5M84.HKD","SG9999015341.SGD","SG9999015978.USD","LU1116320901.HKD","LU0256863902.USD","LU1571399168.USD","LU0256863811.USD","LU0456855351.SGD","LU1201861249.SGD","SG9999001176.SGD","LU1720051108.HKD","LU2089283258.USD","LU0354030511.USD","LU0124676726.USD","LU2168563687.JPY","LU0471298694.HKD","IE00BFTCPJ56.SGD","LU1057294990.SGD","LU1267930573.SGD","LU0133085943.USD","LU2213496289.HKD","LU0070302665.USD","IXJ","IE00BKPKM429.USD","LU0211331839.USD","LU1804176565.USD","MEDI","LU0432979614.USD","IE00BN29S564.USD","IE0005OL40V9.USD","AZNH","LU2552382058.USD","LU2491050154.USD","LU2361045086.USD","IE0001KFT4U8.USD","LU2237443895.HKD","LU1868837300.USD","LU2433249047.HKD","LU0882574139.USD","IE00BJJMRX11.SGD","LU2168564222.USD","LU0158827781.USD","LU2361044949.HKD","LU2552382132.HKD","LU0859254822.USD","SG9999014575.USD","XBI","LU0310800379.SGD","BK4599","LU1066051498.USD","LU2111349929.HKD","LU1066051811.HKD","LU0965509101.SGD","TRUH","LU1061106388.HKD","LU1691799644.USD","LU2087625088.SGD","LU0225771236.USD","LU2361044865.SGD","LU0320765059.SGD","LU1941712264.USD","IE00BZ1G4Q59.USD","IE00B4R5TH58.HKD","SG9999015358.SGD","LU1551013425.SGD","WDNA","IE0004445239.USD","LU0158827948.USD","LU1585245621.USD","LU2750360641.GBP","BK4559","LU0058720904.USD","LU0154236417.USD","LU1069344957.HKD","LU2063271972.USD","LU2417539215.USD","BK4516","LU1868836914.USD","LU1989771016.USD","IE00B19Z3B42.SGD","LU2750360997.AUD","LU0203345920.USD","LU2471134523.USD","LU2112291526.USD","SG9999011175.SGD","LU0820561818.USD","BK4592","LU0648001328.SGD","LU0098860793.USD","SG9999014914.USD","LU1974910355.USD","IE00BKVL7J92.USD","SGXZ81514606.USD","LU1941712348.USD","FHLC","LU0942090050.USD","LU0471298777.SGD","PPH","LU0203201768.USD","LU2168564149.EUR","LU0965508806.USD","THNR","LU1548497426.USD","LU0029864427.USD","LU0238689110.USD","MEDX","BK4501","LU1917777945.USD","LU0130517989.USD","BK4139","MHIP","LU1868837136.USD","LU0786609619.USD","LU0265550359.USD","SGXZ57979304.SGD","IDNA","LU0683600562.USD","LU1366192091.USD","LU2596442595.SGD","LU1929549753.HKD","LU1035773651.USD","LU0861579265.USD","BK4568","LU2089284900.SGD","IE00BJLML261.HKD","IE00BJT1NW94.SGD","LU0672654240.SGD","SGXZ99366536.SGD","LU1934455194.USD","SG9999015986.USD","LU0820562030.AUD","LU0109394709.USD","IE00B1XK9C88.USD","LU1093756168.USD","LU0820561909.HKD","BK4532","LU0109391861.USD","LU0345770993.USD","SG9999014559.SGD","161726","XLV","LU0106261372.USD","SG9999014567.USD","IE000M9KFDE8.USD","SG9999003800.SGD","IE00BBT3K403.USD","IE00B1BXHZ80.USD","LU2461242641.AUD","BK4581","IE0002270589.USD","IE00B7KXQ091.USD","LU2168564495.EUR","LU0354030438.USD","LU0345770308.USD","IE00BK4W5L77.USD","LU2237443465.HKD","SG9999001176.USD","IE00BFSS7M15.SGD","LU2023250330.USD","SG9999014906.USD","SG9999015945.SGD","LU0965509283.SGD","LU0708995401.HKD","LU1116320737.USD","LU0823416689.USD","LU0097036916.USD","LU0316494557.USD","LU0306806265.USD","LU1066051225.USD","LU2125154935.USD","LU2023250843.SGD","LU2471134796.USD","BK4548","LU0174119429.USD","IE00BWXC8680.SGD","LU1162221912.USD","LU1989772923.USD","IE00B19Z3581.USD","MRK","BK7095","LU2896262040.SGD","SG9999002224.SGD","LU2462591350.SGD","IE00BJJMRY28.SGD","IHE","LU1868836591.USD","SG9999001440.SGD","LU2552382215.SGD","LU1868836757.USD","LU0321505439.SGD","LU2357305700.SGD","LU2264538146.SGD","LU0320765489.SGD","LU0203347892.USD","IYH","LU1037948541.HKD","LU1037948897.HKD","LU2125909593.SGD","SG9999013999.USD","LU0477156953.USD","LU1894683348.USD","LU0985320562.USD","LU1127390331.HKD","LU1291159041.SGD","LU0170899867.USD","LU2211815571.USD","LU2471134952.CNY","SGXZ31699556.SGD","CANC","LU2106854487.HKD","LU0466842654.USD","LU2462157665.USD","LU2746668461.USD","LU1814569148.SGD","PAWZ","LU0266013472.USD","BK4588","LU0823434583.USD","LU0985481810.HKD","SG9999018865.SGD","LU2756315318.SGD","PJP","LU2746668974.SGD","LU0210536198.USD","LU0198837287.USD","LU1989772840.SGD","BK4007","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU0208291251.USD","IE00BFSS8Q28.SGD","LU0203202063.USD","SGXZ51526630.SGD","IE00B4JS1V06.HKD","BK4550","IE00BKDWB100.SGD","JDOC","LU0061475181.USD","LU2108987350.USD","SG9999015952.SGD","LU0234572021.USD","LU2089984988.USD","LU2236285917.USD","LU1430594728.SGD","BMED","LU1069347547.HKD","LU0225284248.USD","HRTS","LU0306807586.USD","LU0122379950.USD","LU2265009873.SGD","LU0114720955.EUR","LU0096364046.USD","LU2125909247.SGD","GDOC","LU1699723380.USD","IE00BLSP4452.SGD","LU1979441026.SGD","MRNX","LU1883839398.USD","BK4534","IE0002141913.USD","LGHT","LU1988902786.USD","LU1934455277.USD","BK7104","LU0868494708.USD","LU2237438978.USD","LU2360032135.SGD","LU2023251221.USD","LU1280957306.USD","LU0787776722.HKD","LU0353189680.USD","LU0225283273.USD","FTXH","TMED","IE0004445015.USD","LU1712237335.SGD","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660450919","title":"阿斯利康(AZN.US)單抗新藥兩項適應症在中國上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2660450919","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660450919?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 15:41","pubTimestamp":1787038869,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月17日，阿斯利康宣布，特泽利尤单抗注射液在中国正式上市。2026年3月，特泽利尤单抗基于DIRECTION及WAYPOINT两项3期临床研究的阳性结果，在中国获批两项适应症：用于成人和12岁及以上青少年重度哮喘的维持治疗；本品与鼻用糖皮质激素联合使用，治疗系统性糖皮质激素和/或手术治疗无法充分控制疾病的慢性鼻窦炎伴鼻息肉成人患者。特泽利尤单抗是由阿斯利康与安进合作开发的人源单克隆抗体，可抑制TSLP的活性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481297.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2089984988.USD","LU2237443895.HKD","LU1267930573.SGD","AZN","LU0128525929.USD","LU0432979614.USD","LU0109394709.USD","LU2237443978.SGD","IE00B3T34201.USD","LU2237443382.USD","LU2456880835.USD","LU2237443622.USD","IPOS","LU2417539215.USD","LU1829250122.USD","LU0708994859.HKD","BK4585","LU0289739699.SGD","BK4007","LU2468319806.SGD","LU2462157665.USD","LU0320765992.SGD","LU2237443465.HKD","AZNH","BK4568","LU0889565916.HKD","LU2237443549.SGD","LU2236285917.USD","BK4588","LU0058720904.USD","LU0310800379.SGD","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":1,"totalSize":163,"code":"91000000","status":"200"}]}}